Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II open-label, sequential cohort, dose-escalation study of BMN 111 in children with achondroplasia

Trial Profile

Phase II open-label, sequential cohort, dose-escalation study of BMN 111 in children with achondroplasia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vosoritide (Primary)
  • Indications Achondroplasia
  • Focus Adverse reactions; Proof of concept
  • Sponsors BioMarin Pharmaceutical
  • Most Recent Events

    • 01 Aug 2019 According to BioMarin Pharmaceutical media release, company expects to have over 5 years of clinical data from this Phase 2 study to corroborate maintenance of effect at the time of anticipated marketing application submissions.
    • 04 Jul 2019 Results evaluating use of vosoritide in children with achondroplasia from study 202, 205 and 901 wee published in the New England Journal of Medicine.
    • 18 Jun 2019 According to BioMarin Pharmaceutical media release, data from this trial were published in the New England Journal of Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top